TH168567A - Insulin composition, rapid-acting - Google Patents
Insulin composition, rapid-actingInfo
- Publication number
- TH168567A TH168567A TH1601006639A TH1601006639A TH168567A TH 168567 A TH168567 A TH 168567A TH 1601006639 A TH1601006639 A TH 1601006639A TH 1601006639 A TH1601006639 A TH 1601006639A TH 168567 A TH168567 A TH 168567A
- Authority
- TH
- Thailand
- Prior art keywords
- insulin
- humen
- faster
- analogs
- commercial formulations
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract 26
- 102000004877 Insulin Human genes 0.000 title claims abstract 10
- 108090001061 Insulin Proteins 0.000 title claims abstract 10
- 229940125396 insulin Drugs 0.000 title claims abstract 10
- 239000000203 mixture Substances 0.000 title claims abstract 7
- 238000009472 formulation Methods 0.000 claims abstract 4
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 108010073961 Insulin Aspart Proteins 0.000 claims 1
- 108010065920 Insulin Lispro Proteins 0.000 claims 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims 1
- 229960004717 insulin aspart Drugs 0.000 claims 1
- 108700039926 insulin glulisine Proteins 0.000 claims 1
- 229960000696 insulin glulisine Drugs 0.000 claims 1
- 229960002068 insulin lispro Drugs 0.000 claims 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 abstract 1
Abstract
แก้ไข 20/01/2560 การประดิษฐ์คือองค์ประกอบของฮิวเมนอินซูลินหรืออินซูลินอะนาล็อกที่รวมถึงเทรโพรสทิ นิลและที่มีการทำงานทางเภสัชจลนศาสตร์เร็วกว่าสูตรผสมในเชิงพาณิชย์ของผลิตภัณฑ์อินซูลิน อะนาล็อกที่มีอยู่ ------------------------------------------ การประดิษฐ์คือองค์ประกอบของฮิวเมนอินซูลินหรืออินซูลินอะนาล็อกที่รวมถึง เทรโพรสทินิลและที่มีการทำงานทางเกสัชจลนศาสตร์เร็วกว่าสูตรผสมในเชิงพาณิชย์ของผลิตภัณฑ์ อินซูลินอะนาล็อกที่มีอยู่ สิทธิบัตรยา Revised 20/01/2017 The invention is the composition of humen insulin or insulin analogs that include troprosti. Onyx and with its pharmacokinetics are faster than commercial formulations of insulin products. Analogs available ------------------------------------------ Invention is an element of Humen. Insulin or insulin analogues that include Troprostatinil and it is mechanically active faster than commercial formulations of the product. Existing insulin analog, drug patent
Claims (2)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH168567A true TH168567A (en) | 2017-09-28 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX379267B (en) | FAST-ACTING INSULIN COMPOSITIONS. | |
| GT201700124A (en) | FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP | |
| BR112016015851A2 (en) | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPART | |
| MY191980A (en) | Formulations containing an extract of echinacea and linoleic acid derivatives | |
| EA201700019A1 (en) | HIGHLY PURE ORIENTATION AND METHOD FOR ITS OBTAINING | |
| TH168567A (en) | Insulin composition, rapid-acting | |
| TH1801001060A (en) | Fast acting insulin composition | |
| TR201714964A2 (en) | Effervescent tablet formulations. | |
| TH154912A (en) | Solid pharmaceutical preparations containing levythirosine | |
| TH173865A (en) | External wound healing drugs and external wound healing materials | |
| TH177127A (en) | Stabilized insulin glulisine formulation | |
| TH158486A (en) | Composition of the antibiotic ceftholoxen | |
| TH168501A (en) | Solid composition of triglycerides and their use | |
| TH1701006272A (en) | Ingredient formula containing Diazerine | |
| TH1901007485A (en) | Rapid-acting insulin composition | |
| TH175548A (en) | Hand, foot and mouth disease vaccines and methods for their production and use. | |
| TH1901003956A (en) | components for external use | |
| TH168425A (en) | Elements for the prevention and treatment of mycoplasma infection. | |
| TH176546A (en) | Composition for improvement or prevention of fatty liver in non-alcoholic people. | |
| TH175929A (en) | Antibody Formulation | |
| TH173755A (en) | Pharmaceutical constituents containing lobeglutazone For oral dosing | |
| UA115290U (en) | COMPOSITION IN THE FORM OF SPRAY FOR ORAL APPLICATION CONTAINING CHOLINE ALPHOSCERATE | |
| ITUA20163937A1 (en) | Vehicle for the administration of active ingredients and / or functional ingredients, and compositions containing the same. | |
| TH168864A (en) | Fixed ratio formulation of insulin glargene / lixisinatide. | |
| TH170857A (en) | Anti fatigue agent |